Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | WEE1 | P30291 | 12/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21876515 | 0.96 | EGFR (0.54) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876514 | 0.95 | WEE1 (0.56) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876454 | 0.93 | WEE1 (0.50) | EGFRWEE1TNK2KCNH2JAK2 | |
| SCHEMBL21876457 | 0.91 | WEE1 (0.59) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL29569653 | 0.90 | WEE1 (0.54) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL20649234 | 0.90 | WEE1 (0.54) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876484 | 0.90 | WEE1 (0.56) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876482 | 0.86 | EGFR (0.54) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876481 | 0.85 | WEE1 (0.57) | EGFRWEE1TNK2KCNH2CYP3A4 | |
| SCHEMBL21876456 | 0.85 | WEE1 (0.58) | EGFRWEE1TNK2KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | claimed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | claimed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | claimed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | disclosed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | WEE1, WEE2, CCNE1 | EGFR 1013/4885WEE1 1/4885TNK2 76/4885 |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | WEE1, WEE2, EZH2 | EGFR 554/4885WEE1 1/4885TNK2 254/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | EGFR 1013/4885WEE1 1/4885TNK2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.